Income Taxes (Notes) |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Income Tax Disclosure [Abstract] | |
| Income Tax Disclosure [Text Block] | INCOME TAXES The Company’s provision for income taxes is based on the estimated annual effective tax rate, plus discrete items. The effective tax rates for the three months ended March 31, 2026 and 2025 were (17)% and (77)%, respectively. The difference between the Company’s effective tax rates for the 2026 and 2025 periods and the U.S. statutory tax rate of 21% related primarily to foreign tax rate differentials, the impacts of foreign currency fluctuations at certain foreign subsidiaries, nondeductible expenses, valuation allowance, the impacts of U.S. investment tax credits (“ITCs”), and noncontrolling interest in our U.S. subsidiaries. For the three months ended March 31, 2026, the Company recorded discrete tax benefit of approximately $27 million associated with the merger of Cochrane into AES Andes and discrete tax expense of approximately $36 million resulting from allocations of losses to tax equity investors on renewables projects. For the three months ended March 31, 2025, the Company recognized discrete tax expense of approximately $26 million resulting from allocations of losses to tax equity investors on renewables projects.
|